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An example of the increased frequency of interventional procedures of this growth is shown in Figure 1 . It gives estimates of the number of radio-frequency (RF) cardiac catheter ablation procedures performed per year from a survey of 157 electrophysiology laboratories (5) . The introduction of an array of new devices to facilitate the interventional treatment of a variety of vascular and other conditions is also contributing to increased numbers of interventional procedures. All reports of radiation injury resulting from fluoroscopy which have come to the attention of the FDA have been investigated to determine the nature and circumstances of the injury. The reports are usually received through the manufacturer of the x-ray system and contain minimal information regarding the circumstances of the injury. The investigation was conducted by telephone calls, letters and personal visits to the facilities or individuals involved. Provision of additional information to the FDA was voluntary and a majority of the facilities contacted declined to provide additional information due to concerns regarding liability or confidentiality. Table 1 is a summary of the types of interventional procedures which have resulted in reports of skin injuries and the number of each type which have come to the attention of the FDA. The severity of the injuries reported range from erythema in a few cases, through moist desquamation, to skin necrosis requiring skin grafting for treatment in the most serious cases. It is very probable that the injuries which have come to the attention of the FDA represent an unknown fraction of the total number of radiation-induced injuries resulting from fluoroscopicallyguided procedures. Table 2 . These are selected to illustrate the range of procedures and the severity of the injuries reported. The attempted investigation of the majority of the incidents was unsuccessful in determining information which would permit estimation of the absorbed doses to the skin which occurred. Either no records were maintained of the extent of the fluoroscopic exposure time and other technique factors or the facility was unwilling to share additional information because of ongoing legal actions or concerns regarding liability or adverse publicity. Table 3 presents an example of the magnitude of the skin exposures which can result from a complex case involving multiple diagnostic and therapeutic procedures. The patient required multiple hepatic and biliary procedures, including percutaneous cholangiography, mesenteric angiography and multiple embolization procedures during a four-week period. The patient received an unknown amount of exposure from procedures performed prior to arrival at the tertiary care facility. The estimates of skin exposure were made by staff of the facility from data on system technique factors, total fluoroscopic exposure times, number of digital subtraction angiography frames, exposure rates during fluoroscopy and exposure per frame during DSA, patient thickness and system geometry which were recorded by the facility under a program instituted to monitor patient exposures. (1) Procedures performed during four-week period. Estimates are of entrance skin exposure and do not include backscatter.
(2) Two different fluoroscopy systems were used, due to equipment failure, and multiple dose rates (magnification modes) were used.
(3) Total exposure may not have been delivered to a single area of skin due to movement of x-ray beam. Location of beam not monitored during various procedures. The total skin exposure given in Table 3 of 650 x 10 -3 C/kg (2,522 R), is not localized to a specific area of skin; the location and size of the irradiated area varied with procedure and projection. The x-ray field sizes and entrance field locations were not monitored during the procedures. However, most of the irradiation would have been to the area of the lower right back with a significant probability of overlapping of fields. Thus, the total exposure from Table 3 is an upper limit on the exposure to any specific area of skin and provides an indication that the potential for skin injury was significant in this case. In addition, the effect of dose fractionation due to the dose being delivered over a four-week period further complicates the estimation of the expected severity of the injury. Whether skin injury resulted from this series of procedures is unknown because the patient died two days after the last procedure.
An example of a skin injury attributable to x-rays from fluoroscopy is shown in Figure 2 . This case, patient A in Table 2 , is that of a 40-year-old male who underwent coronary angiography, coronary angioplasty and a second angiography procedure due to complications, followed by a coronary artery by-pass graft, all on March 29, 1990. Figure 2(a) shows the area of injury six to eight weeks following the procedures. The injury was described as "turning red about one month after the procedure and peeling a week later." In mid-May 1990, it had the appearance of a second-degree burn. Figure 2(b) shows the condition in late summer 1990, exact date unknown, with the appearance of a healed burn, except for a small ulcerated area present near the center. Skin breakdown continued over the following months with progressive necrosis, Figure 2 (c and d) . The injury eventually required a skin graft as shown in Figure 2 (e). The magnitude of the skin dose received by this patient is not known. However, from the nature of the injury, it is probable that the dose exceeded 20 Gy. Download 432 x 576 63kB JPEG image. Review of the circumstances of many of the injuries revealed a lack of appreciation by the physicians performing these procedures, prior to observing the injury, of the magnitude of the skin doses which can result from the long exposure times which may be required by complex interventional procedures. This observation led the FDA to issue a Public Health Advisory on September 30, 1994, to alert the radiological community to this concern and to suggest actions which should be taken to reduce the potential for radiation-induced skin injuries (1). These actions included:
 Establishing standard procedures and protocols for each procedure, including consideration of fluoroscopy exposure time,  Determining the radiation dose rates for specific fluoroscopy systems and for all operating modes,  Assessing each protocol for the potential for radiation injury to the patient,  Modifying protocols, when appropriate, to minimize cumulative absorbed dose to any specific skin area and using equipment which aids in minimizing absorbed dose.
FDA also suggested that information be recorded in the patient's record which would permit estimation of absorbed dose to the skin from interventional procedures.
In a September 15, 1995, follow-up to this suggestion, FDA recommended that the facility record in the patient's medical record information regarding absorbed dose to the skin for any procedure with the potential for a skin dose approaching or exceeding some threshold dose for injury (7) . This threshold dose for the recording of data should be established by the facility. FDA suggests a threshold absorbed dose in skin of 1 Gy. The following procedures are likely to meet this criterion due to their potential for long exposure times: Radio frequency cardiac catheter ablation Vascular embolization
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